Heribert Schunkert, MD, of the German Heart Center in Munich, Germany, talks with DocWire News about the TiCAB trial results that he presented at the American Heart Association 2018 Scientific Sessions in Chicago.
Researchers for the Ticagrelor versus Aspirin in Patients Undergoing Coronary Bypass Surgery (TiCAB) trial, seeking to clarify the balance between bleeding and thrombotic risks with antiplatelet treatment strategy in coronary artery bypass graft (CABG) patients, randomly assigned patients scheduled for CABG (1:1) to receive either 100 mg aspirin once daily or ticagrelor 90 mg twice daily. The primary study outcome was a composite of cardiovascular death, myocardial infarction, repeat revascularization, and stroke at one year post-CABG. The primary safety endpoint was major bleeding.
To read the results, see DocWire News’ coverage of the trial at AHA 2018.